Detalhe da pesquisa
1.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34462870
2.
Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study.
BMC Cancer
; 22(1): 168, 2022 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35164713
3.
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
J Transl Med
; 19(1): 270, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34167578
4.
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.
Anticancer Drugs
; 28(5): 551-556, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28296649
5.
Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Eur J Clin Pharmacol
; 73(2): 157-164, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27864592
6.
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Clin Cancer Res
; 29(14): 2714-2724, 2023 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37125965
7.
Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data?
Cancers (Basel)
; 14(17)2022 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36077726
8.
Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot Study.
Cancers (Basel)
; 14(6)2022 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35326693
9.
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak.
Ther Adv Urol
; 13: 17562872211054302, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34707691
10.
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
Eur J Cancer
; 142: 18-28, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33212418
11.
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.
J Immunother Cancer
; 8(2)2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33154150
12.
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
Eur J Cancer
; 134: 19-28, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32454395
13.
Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience.
Radiat Oncol
; 14(1): 205, 2019 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727093
14.
Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC.
Anticancer Res
; 38(11): 6029-6039, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30396917
15.
Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report.
Semin Arthritis Rheum
; 48(2): e17-e20, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29402438